Equillium, Inc.
Equillium, Inc. (EQ): 6 pipeline candidates · ~43 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
43.0 months
D/E 0.06 · 52% dilution
Lead: Phase 3
6 candidates
N/A
0 buys · 14 sells (180d)
A transparent, data-derived signal for Equillium, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$189.0M
Cash
$61.3M
Quarterly Burn
$4.3M
Runway
43.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| eq001 | Phase 1/Phase 2 |
| eq101 | Phase 2 |
| eq302 | Preclinical |
| eq504 | Preclinical |
| itolizumab | Phase 3 |
| itolizumab [bmab 600] | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$72.2M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 12,989,142 | $25.9M |
| adage capital partners gp, l.l.c. | 5,329,416 | $10.7M |
| adar1 capital management, llc | 3,726,659 | $7.5M |
| vanguard capital management llc | 3,568,944 | $7.1M |
| ra capital management, l.p. | 3,096,336 | $6.2M |
| balyasny asset management l.p. | 1,638,770 | $3.3M |
| affinity asset advisors, llc | 1,226,310 | $2.5M |
| renaissance technologies llc | 656,964 | $1.3M |
| diadema partners lp | 433,844 | $868K |
| hudson bay capital management lp | 428,538 | $857K |
Showing top 10 of 46 institutional holders of Equillium, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Equillium, Inc.'s pipeline?
Equillium, Inc. (EQ) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Equillium, Inc.'s lead drug candidate?
Equillium, Inc.'s most advanced tracked candidate is eq001 (Phase 1/Phase 2) for Acute-graft-versus-host Disease.
What is Equillium, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Equillium, Inc. has approximately 43.0 months of cash runway.
What is Equillium, Inc.'s market capitalization?
Equillium, Inc.'s market capitalization is approximately $189.0M.
Who is the CEO of Equillium, Inc.?
Mr. Bruce D. Steel C.F.A. is the chief executive officer of Equillium, Inc. (EQ).
Get the full picture on Equillium, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.